iSpecimen Inc. Overview
Pro stress-test →iSpecimen operates a live, revenue-generating digital marketplace for human biospecimens—the raw materials of scientific discovery. Researchers can log in, search by disease state, demographics, or processing requirements to get exactly what they need, while hospitals and labs monetize their surplus inventory. The platform addresses a critical inefficiency in medical research: the tedious, manual process of sourcing biological samples.
Strategic Profile
Pro stress-test →With millions in revenue and repeatable transactions that generate real dollars, iSpecimen operates a steadier model than biotech companies betting everything on FDA calendars. The company is planting flags across high-value medical fields, partnering with U.S. cancer centers for precision oncology research and accessing more than 600,000 patients across multi-state partnerships for women's health samples.
Competitive Landscape
Pro stress-test →iSpecimen occupies a unique niche at the intersection of logistics, life sciences, and digital infrastructure that lacks direct public competitors. Indirect competition comes from traditional biospecimen sourcing (manual, fragmented), academic biobanks, and specialized tissue banks. The platform advantage lies in standardization, speed, and compliance handling across a fragmented $13.5B market expected to exceed this threshold by 2032.
Industry Context
iSpecimen Inc. operates in Life Sciences / Medical Research / Digital Marketplace / Biospecimen Sourcing.
Key facts
Founded: 2009 · Headquarters: Woburn, Massachusetts, US · Revenue: $9.29M (FY2024) · Market cap: $0.10B (approximately $100M based on 0.25 stock price)